Toll Free: 1-888-928-9744

Transplantation Drug Development Pipeline Review, 2017

Published: Jul 1, 2017 | Pages: 242 | Publisher: GBI Research | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Transplantation Drug Development Pipeline Review, 2017

Summary

This report provides an overview of the transplantation pipeline landscape, specifically covering drugs used to prevent and treat organ rejection and graft-versus-host disease. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for graft-versus-host disease (GVHD), and the rejection of bone, liver, kidney, lung and heart transplants.

Transplant rejection is a complication that can occur after the replacement of a defective host organ with a foreign donor organ. General risks associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Additionally, following a transplant, the immune system may consider the transplanted heart as foreign and mount a response against it, especially if the antigens expressed by the tissues in each do not match. Generally, immunosuppressive drugs are administered simultaneously with the transplant in order to minimize this risk. These immunosuppressive drugs prevent the body from either identifying or attacking the foreign organ via various immune responses thus blocking organ rejection and facilitating a successful transplant.

The size of these pipelines ranges from seven products in heart transplantation to 121 in bone marrow transplantation. A wide range of targets, including integrins, chemokine receptors, protein kinases and cadherins are being developed, with no particular class of target predominating in terms of pipeline volume within each indication. However, there is a clear trend towards immune system molecular targets being studied, reflecting the underlying immune-based pathophysiology of these indications.

Scope

- Which companies are the most active within the pipeline for transplantation therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of transplantation therapeutics?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
 Table of Contents

GBI Research Report Guidance 2
Executive Summary 3
Table of Contents 4
List of Tables 6
List of Figures 12
Introduction 14
Transplantation Report Coverage 14
Bone Marrow Transplant Rejection - Overview 14
Graft Versus Host Disease (GVHD) - Overview 14
Liver Transplant Rejection - Overview 14
Kidney Transplant Rejection - Overview 14
Lung Transplant Rejection - Overview 14
Heart Transplant Rejection - Overview 15
Therapeutics Development 16
Bone Marrow Transplant Rejection 16
Graft Versus Host Disease (GVHD) 27
Liver Transplant Rejection 38
Kidney Transplant Rejection 42
Lung Transplant Rejection 48
Heart Transplant Rejection 51
Therapeutics Assessment 52
Bone Marrow Transplant Rejection 52
Graft Versus Host Disease (GVHD) 62
Liver Transplant Rejection 72
Kidney Transplant Rejection 80
Lung Transplant Rejection 88
Heart Transplant Rejection 96
Companies Involved in Therapeutics Development 104
Bone Marrow Transplant Rejection 104
Graft Versus Host Disease (GVHD) 139
Liver Transplant Rejection 170
Kidney Transplant Rejection 173
Lung Transplant Rejection 185
Heart Transplant Rejection 187
Dormant Projects 189
Bone Marrow Transplant Rejection 189
Graft Versus Host Disease (GVHD) 192
Liver Transplant Rejection 195
Kidney Transplant Rejection 196
Lung Transplant Rejection 198
Heart Transplant Rejection 198
Discontinued Products 199
Bone Marrow Transplant Rejection 199
Graft Versus Host Disease (GVHD) 199
Liver Transplant Rejection 200
Kidney Transplant Rejection 200
Product Development Milestones 201
Bone Marrow Transplant Rejection 201
Graft Versus Host Disease (GVHD) 212
Liver Transplant Rejection 223
Kidney Transplant Rejection 225
Lung Transplant Rejection 234
Appendix 241
Methodology 241
Coverage 241
Secondary Research 241
Primary Research 241
Expert Panel Validation 241
Contact Us 241
Disclaimer 242
List of Tables

Number of Products under Development for Bone Marrow Transplant Rejection 16
Number of Products under Development by Companies, Bone Marrow Transplant Rejection 18
Number of Products under Development by Universities/Institutes, Bone Marrow Transplant Rejection 21
Products under Development by Companies, Bone Marrow Transplant Rejection 22
Products under Development by Universities/Institutes, Bone Marrow Transplant Rejection 26
Number of Products under Development for Graft Versus Host Disease (GVHD) 27
Number of Products under Development by Companies, Graft Versus Host Disease (GVHD) 29
Number of Products under Development by Universities/Institutes, Graft Versus Host Disease (GVHD) 32
Products under Development by Companies, Graft Versus Host Disease (GVHD) 33
Products under Development by Universities/Institutes, Graft Versus Host Disease (GVHD) 37
Number of Products under Development for Liver Transplant Rejection 38
Number of Products under Development by Companies, Liver Transplant Rejection 39
Number of Products under Development by Universities/Institutes, Liver Transplant Rejection 40
Products under Development by Companies, Liver Transplant Rejection 41
Products under Development by Universities/Institutes, Liver Transplant Rejection 41
Number of Products under Development for Kidney Transplant Rejection 42
Number of Products under Development by Companies, Kidney Transplant Rejection 44
Number of Products under Development by Universities/Institutes, Kidney Transplant Rejection 45
Products under Development by Companies, Kidney Transplant Rejection 46
Products under Development by Universities/Institutes, Kidney Transplant Rejection 47
Number of Products under Development for Lung Transplant Rejection 48
Number of Products under Development by Companies, Lung Transplant Rejection 49
Products under Development by Companies, Lung Transplant Rejection 50
Number of Products under Development for Heart Transplant Rejection 51
Number of Products under Development by Companies, Heart Transplant Rejection 51
Products under Development by Companies, Heart Transplant Rejection 51
Number of Products by Stage and Target, Bone Marrow Transplant Rejection 53
Number of Products by Stage and Mechanism of Action, Bone Marrow Transplant Rejection 56
Number of Products by Stage and Route of Administration, Bone Marrow Transplant Rejection 59
Number of Products by Stage and Molecule Type, Bone Marrow Transplant Rejection 61
Number of Products by Stage and Target, Graft Versus Host Disease (GVHD) 63
Number of Products by Stage and Mechanism of Action, Graft Versus Host Disease (GVHD) 66
Number of Products by Stage and Route of Administration, Graft Versus Host Disease (GVHD) 69
Number of Products by Stage and Molecule Type, Graft Versus Host Disease (GVHD) 71
Number of Products by Stage and Target, Liver Transplant Rejection 73
Number of Products by Stage and Mechanism of Action, Liver Transplant Rejection 75
Number of Products by Stage and Route of Administration, Liver Transplant Rejection 77
Number of Products by Stage and Molecule Type, Liver Transplant Rejection 79
Number of Products by Stage and Target, Kidney Transplant Rejection 81
Number of Products by Stage and Mechanism of Action, Kidney Transplant Rejection 83
Number of Products by Stage and Route of Administration, Kidney Transplant Rejection 85
Number of Products by Stage and Molecule Type, Kidney Transplant Rejection 87
Number of Products by Stage and Target, Lung Transplant Rejection 89
Number of Products by Stage and Mechanism of Action, Lung Transplant Rejection 91
Number of Products by Stage and Route of Administration, Lung Transplant Rejection 93
Number of Products by Stage and Molecule Type, Lung Transplant Rejection 95
Number of Products by Stage and Target, Heart Transplant Rejection 97
Number of Products by Stage and Mechanism of Action, Heart Transplant Rejection 99
Number of Products by Stage and Route of Administration, Heart Transplant Rejection 101
Number of Products by Stage and Molecule Type, Heart Transplant Rejection 103
Bone Marrow Transplant Rejection - Pipeline by AbbVie Inc 104
Bone Marrow Transplant Rejection - Pipeline by AbGenomics International Inc 104
Bone Marrow Transplant Rejection - Pipeline by Actelion Ltd 105
Bone Marrow Transplant Rejection - Pipeline by Alexion Pharmaceuticals Inc 105
Bone Marrow Transplant Rejection - Pipeline by Allergan Plc 106
Bone Marrow Transplant Rejection - Pipeline by Amunix Operating Inc 106
Bone Marrow Transplant Rejection - Pipeline by AnaptysBio Inc 107
Bone Marrow Transplant Rejection - Pipeline by apceth Biopharma GmbH 107
Bone Marrow Transplant Rejection - Pipeline by Aptevo Therapeutics Inc 108
Bone Marrow Transplant Rejection - Pipeline by arGEN-X BV 108
Bone Marrow Transplant Rejection - Pipeline by Athersys Inc 109
Bone Marrow Transplant Rejection - Pipeline by Bellicum Pharmaceuticals Inc 109
Bone Marrow Transplant Rejection - Pipeline by Bio-Cancer Treatment International Ltd 110
Bone Marrow Transplant Rejection - Pipeline by Biogen Inc 110
Bone Marrow Transplant Rejection - Pipeline by Bristol-Myers Squibb Company 111
Bone Marrow Transplant Rejection - Pipeline by Cantex Pharmaceuticals Inc 111
Bone Marrow Transplant Rejection - Pipeline by Capricor Therapeutics Inc 112
Bone Marrow Transplant Rejection - Pipeline by Cell Source Inc 112
Bone Marrow Transplant Rejection - Pipeline by Cell2B Advanced Therapeutics SA 113
Bone Marrow Transplant Rejection - Pipeline by CellECT Bio Inc 113
Bone Marrow Transplant Rejection - Pipeline by Cleveland BioLabs Inc 114
Bone Marrow Transplant Rejection - Pipeline by Compugen Ltd 114
Bone Marrow Transplant Rejection - Pipeline by Cynata Therapeutics Limited 115
Bone Marrow Transplant Rejection - Pipeline by Cytodyn Inc 115
Bone Marrow Transplant Rejection - Pipeline by Dompe Farmaceutici SpA 116
Bone Marrow Transplant Rejection - Pipeline by Dr. Falk Pharma GmbH 116
Bone Marrow Transplant Rejection - Pipeline by Escape Therapeutics Inc 117
Bone Marrow Transplant Rejection - Pipeline by F. Hoffmann-La Roche Ltd 117
Bone Marrow Transplant Rejection - Pipeline by Fate Therapeutics Inc 118
Bone Marrow Transplant Rejection - Pipeline by Generon (Shanghai) Corp Ltd 118
Bone Marrow Transplant Rejection - Pipeline by Gilead Sciences Inc 119
Bone Marrow Transplant Rejection - Pipeline by GlaxoSmithKline Plc 119
Bone Marrow Transplant Rejection - Pipeline by Immunomedics Inc 120
Bone Marrow Transplant Rejection - Pipeline by Incyte Corp 120
Bone Marrow Transplant Rejection - Pipeline by Jazz Pharmaceuticals Plc 121
Bone Marrow Transplant Rejection - Pipeline by Kadmon Corp LLC 121
Bone Marrow Transplant Rejection - Pipeline by Kamada Ltd 122
Bone Marrow Transplant Rejection - Pipeline by Kiadis Pharma NV 122
Bone Marrow Transplant Rejection - Pipeline by Kymab Ltd 123
Bone Marrow Transplant Rejection - Pipeline by Kyorin Pharmaceutical Co Ltd 123
Bone Marrow Transplant Rejection - Pipeline by MacroGenics Inc 124
Bone Marrow Transplant Rejection - Pipeline by Mallinckrodt Plc 124
Bone Marrow Transplant Rejection - Pipeline by Medsenic 125
Bone Marrow Transplant Rejection - Pipeline by Mesoblast Ltd 125
Bone Marrow Transplant Rejection - Pipeline by Millennium Pharmaceuticals Inc 126
Bone Marrow Transplant Rejection - Pipeline by Nektar Therapeutics 126
Bone Marrow Transplant Rejection - Pipeline by Neovii Pharmaceuticals AG 127
Bone Marrow Transplant Rejection - Pipeline by Nohla Therapeutics Inc 127
Bone Marrow Transplant Rejection - Pipeline by Novartis AG 128
Bone Marrow Transplant Rejection - Pipeline by OncoImmune Inc 128
Bone Marrow Transplant Rejection - Pipeline by OSE Immunotherapeutics 129
Bone Marrow Transplant Rejection - Pipeline by Pfizer Inc 129
Bone Marrow Transplant Rejection - Pipeline by Pharmicell Co Ltd 130
Bone Marrow Transplant Rejection - Pipeline by Pluristem Therapeutics Inc 130
Bone Marrow Transplant Rejection - Pipeline by REGiMMUNE Corp 131
Bone Marrow Transplant Rejection - Pipeline by Sanofi 131
Bone Marrow Transplant Rejection - Pipeline by Sarepta Therapeutics Inc 132
Bone Marrow Transplant Rejection - Pipeline by Seattle Genetics Inc 132
Bone Marrow Transplant Rejection - Pipeline by Seres Therapeutics Inc 133
Bone Marrow Transplant Rejection - Pipeline by Sigmoid Pharma Ltd 133
Bone Marrow Transplant Rejection - Pipeline by Synedgen Inc 134
Bone Marrow Transplant Rejection - Pipeline by Taiga Biotechnologies Inc 134
Bone Marrow Transplant Rejection - Pipeline by Takeda Pharmaceutical Company Ltd 135
Bone Marrow Transplant Rejection - Pipeline by Targazyme Inc 135
Bone Marrow Transplant Rejection - Pipeline by United BioPharma Inc 136
Bone Marrow Transplant Rejection - Pipeline by Vault Pharma Inc 136
Bone Marrow Transplant Rejection - Pipeline by VBI Vaccines Inc 137
Bone Marrow Transplant Rejection - Pipeline by Xenikos BV 137
Bone Marrow Transplant Rejection - Pipeline by XL-protein GmbH 138
Bone Marrow Transplant Rejection - Pipeline by ZIOPHARM Oncology Inc 138
Graft Versus Host Disease (GVHD) - Pipeline by AbbVie Inc 139
Graft Versus Host Disease (GVHD) - Pipeline by AbGenomics International Inc 139
Graft Versus Host Disease (GVHD) - Pipeline by Allergan Plc 140
Graft Versus Host Disease (GVHD) - Pipeline by Amunix Operating Inc 140
Graft Versus Host Disease (GVHD) - Pipeline by AnaptysBio Inc 141
Graft Versus Host Disease (GVHD) - Pipeline by apceth Biopharma GmbH 141
Graft Versus Host Disease (GVHD) - Pipeline by Aptevo Therapeutics Inc 142
Graft Versus Host Disease (GVHD) - Pipeline by arGEN-X BV 142
Graft Versus Host Disease (GVHD) - Pipeline by Athersys Inc 143
Graft Versus Host Disease (GVHD) - Pipeline by Bellicum Pharmaceuticals Inc 143
Graft Versus Host Disease (GVHD) - Pipeline by Bio-Cancer Treatment International Ltd 144
Graft Versus Host Disease (GVHD) - Pipeline by Biogen Inc 144
Graft Versus Host Disease (GVHD) - Pipeline by Bristol-Myers Squibb Company 145
Graft Versus Host Disease (GVHD) - Pipeline by Capricor Therapeutics Inc 145
Graft Versus Host Disease (GVHD) - Pipeline by Cell2B Advanced Therapeutics SA 146
Graft Versus Host Disease (GVHD) - Pipeline by CellECT Bio Inc 146
Graft Versus Host Disease (GVHD) - Pipeline by Commence Bio Inc 147
Graft Versus Host Disease (GVHD) - Pipeline by Cynata Therapeutics Ltd 147
Graft Versus Host Disease (GVHD) - Pipeline by Cytodyn Inc 148
Graft Versus Host Disease (GVHD) - Pipeline by Dr. Falk Pharma GmbH 148
Graft Versus Host Disease (GVHD) - Pipeline by Escape Therapeutics Inc 149
Graft Versus Host Disease (GVHD) - Pipeline by F. Hoffmann-La Roche Ltd 149
Graft Versus Host Disease (GVHD) - Pipeline by Fate Therapeutics Inc 150
Graft Versus Host Disease (GVHD) - Pipeline by Generon (Shanghai) Corp Ltd 150
Graft Versus Host Disease (GVHD) - Pipeline by Gilead Sciences Inc 151
Graft Versus Host Disease (GVHD) - Pipeline by GlaxoSmithKline Plc 151
Graft Versus Host Disease (GVHD) - Pipeline by Incyte Corp 152
Graft Versus Host Disease (GVHD) - Pipeline by Jazz Pharmaceuticals Plc 152
Graft Versus Host Disease (GVHD) - Pipeline by Kadmon Corp LLC 153
Graft Versus Host Disease (GVHD) - Pipeline by Kamada Ltd 153
Graft Versus Host Disease (GVHD) - Pipeline by Kiadis Pharma NV 154
Graft Versus Host Disease (GVHD) - Pipeline by Kymab Ltd 154
Graft Versus Host Disease (GVHD) - Pipeline by Kyorin Pharmaceutical Co Ltd 155
Graft Versus Host Disease (GVHD) - Pipeline by MacroGenics Inc 155
Graft Versus Host Disease (GVHD) - Pipeline by Mallinckrodt Plc 156
Graft Versus Host Disease (GVHD) - Pipeline by Mesoblast Ltd 156
Graft Versus Host Disease (GVHD) - Pipeline by Millennium Pharmaceuticals Inc 157
Graft Versus Host Disease (GVHD) - Pipeline by Nektar Therapeutics 157
Graft Versus Host Disease (GVHD) - Pipeline by Nohla Therapeutics Inc 158
Graft Versus Host Disease (GVHD) - Pipeline by Novartis AG 158
Graft Versus Host Disease (GVHD) - Pipeline by OncoImmune Inc 159
Graft Versus Host Disease (GVHD) - Pipeline by OSE Immunotherapeutics 159
Graft Versus Host Disease (GVHD) - Pipeline by Pfizer Inc 160
Graft Versus Host Disease (GVHD) - Pipeline by Pharmicell Co Ltd 160
Graft Versus Host Disease (GVHD) - Pipeline by REGiMMUNE Corp 161
Graft Versus Host Disease (GVHD) - Pipeline by Sanofi 161
Graft Versus Host Disease (GVHD) - Pipeline by Sarepta Therapeutics Inc 162
Graft Versus Host Disease (GVHD) - Pipeline by Seattle Genetics Inc 162
Graft Versus Host Disease (GVHD) - Pipeline by Seres Therapeutics Inc 163
Graft Versus Host Disease (GVHD) - Pipeline by Sigmoid Pharma Ltd 163
Graft Versus Host Disease (GVHD) - Pipeline by Synedgen Inc 164
Graft Versus Host Disease (GVHD) - Pipeline by Takeda Pharmaceutical Company Ltd 164
Graft Versus Host Disease (GVHD) - Pipeline by Targazyme Inc 165
Graft Versus Host Disease (GVHD) - Pipeline by TC BioPharm Ltd 165
Graft Versus Host Disease (GVHD) - Pipeline by TxCell SA 166
Graft Versus Host Disease (GVHD) - Pipeline by United BioPharma Inc 166
Graft Versus Host Disease (GVHD) - Pipeline by Vault Pharma Inc 167
Graft Versus Host Disease (GVHD) - Pipeline by VBI Vaccines Inc 167
Graft Versus Host Disease (GVHD) - Pipeline by Xenikos BV 168
Graft Versus Host Disease (GVHD) - Pipeline by XL-protein GmbH 168
Graft Versus Host Disease (GVHD) - Pipeline by ZIOPHARM Oncology Inc 169
Liver Transplant Rejection - Pipeline by Astellas Pharma Inc 170
Liver Transplant Rejection - Pipeline by Biogen Inc 170
Liver Transplant Rejection - Pipeline by Conatus Pharmaceuticals Inc 171
Liver Transplant Rejection - Pipeline by Dompe Farmaceutici SpA 171
Liver Transplant Rejection - Pipeline by Novartis AG 172
Liver Transplant Rejection - Pipeline by RedHill Biopharma Ltd 172
Kidney Transplant Rejection - Pipeline by Amgen Inc 173
Kidney Transplant Rejection - Pipeline by Angion Biomedica Corp 173
Kidney Transplant Rejection - Pipeline by Apellis Pharmaceuticals Inc 174
Kidney Transplant Rejection - Pipeline by Astellas Pharma Inc 174
Kidney Transplant Rejection - Pipeline by Biogen Inc 175
Kidney Transplant Rejection - Pipeline by Catalyst Biosciences Inc 175
Kidney Transplant Rejection - Pipeline by Corline Biomedical AB 176
Kidney Transplant Rejection - Pipeline by CSL Ltd 176
Kidney Transplant Rejection - Pipeline by GlaxoSmithKline Plc 177
Kidney Transplant Rejection - Pipeline by Grifols SA 177
Kidney Transplant Rejection - Pipeline by Hansa Medical AB 178
Kidney Transplant Rejection - Pipeline by Kyowa Hakko Kirin Co Ltd 178
Kidney Transplant Rejection - Pipeline by Magnus Life Ltd 179
Kidney Transplant Rejection - Pipeline by Noorik Biopharmaceuticals AG 179
Kidney Transplant Rejection - Pipeline by Novartis AG 180
Kidney Transplant Rejection - Pipeline by Opsona Therapeutics Ltd 180
Kidney Transplant Rejection - Pipeline by OSE Immunotherapeutics 181
Kidney Transplant Rejection - Pipeline by Pharmicell Co Ltd 181
Kidney Transplant Rejection - Pipeline by Pharming Group NV 182
Kidney Transplant Rejection - Pipeline by Prolong Pharmaceuticals LLC 182
Kidney Transplant Rejection - Pipeline by Quark Pharmaceuticals Inc 183
Kidney Transplant Rejection - Pipeline by Shire Plc 183
Kidney Transplant Rejection - Pipeline by Tiziana Life Sciences Plc 184
Lung Transplant Rejection - Pipeline by Apeptico Forschung und Entwicklung GmbH 185
Lung Transplant Rejection - Pipeline by Dompe Farmaceutici SpA 185
Lung Transplant Rejection - Pipeline by Kamada Ltd 186
Lung Transplant Rejection - Pipeline by Novartis AG 186
Lung Transplant Rejection - Pipeline by Quark Pharmaceuticals Inc 187
Heart Transplant Rejection - Pipeline by Astellas Pharma Inc 187
Heart Transplant Rejection - Pipeline by Heat Biologics Inc 188
Heart Transplant Rejection - Pipeline by Noxxon Pharma AG 188
Bone Marrow Transplant Rejection - Dormant Projects 189
Graft Versus Host Disease (GVHD) - Dormant Projects 192
Liver Transplant Rejection - Dormant Projects 195
Kidney Transplant Rejection - Dormant Projects 196
Lung Transplant Rejection - Dormant Projects 198
Heart Transplant Rejection - Dormant Projects 198
Bone Marrow Transplant Rejection - Discontinued Products 199
Graft Versus Host Disease (GVHD) - Discontinued Products 199
Liver Transplant Rejection - Discontinued Products 200
Kidney Transplant Rejection - Discontinued Products 200

List of Figures

Number of Products under Development for Bone Marrow Transplant Rejection 16
Number of Products under Development by Companies, Bone Marrow Transplant Rejection 17
Number of Products under Development by Universities/Institutes, Bone Marrow Transplant Rejection 20
Number of Products under Development for Graft Versus Host Disease (GVHD) 27
Number of Products under Development by Companies, Graft Versus Host Disease (GVHD) 28
Number of Products under Development by Universities/Institutes, Graft Versus Host Disease (GVHD) 31
Number of Products under Development for Liver Transplant Rejection 38
Number of Products under Development by Companies, Liver Transplant Rejection 39
Number of Products under Development by Universities/Institutes, Liver Transplant Rejection 40
Number of Products under Development for Kidney Transplant Rejection 42
Number of Products under Development by Companies, Kidney Transplant Rejection 43
Number of Products under Development by Universities/Institutes, Kidney Transplant Rejection 45
Number of Products under Development for Lung Transplant Rejection 48
Number of Products under Development by Companies, Lung Transplant Rejection 49
Number of Products by Top 10 Targets, Bone Marrow Transplant Rejection 52
Number of Products by Stage and Top 10 Targets, Bone Marrow Transplant Rejection 52
Number of Products by Top 10 Mechanism of Actions, Bone Marrow Transplant Rejection 55
Number of Products by Stage and Top 10 Mechanism of Actions, Bone Marrow Transplant Rejection 55
Number of Products by Routes of Administration, Bone Marrow Transplant Rejection 58
Number of Products by Stage and Routes of Administration, Bone Marrow Transplant Rejection 58
Number of Products by Top 10 Molecule Types, Bone Marrow Transplant Rejection 60
Number of Products by Stage and Top 10 Molecule Types, Bone Marrow Transplant Rejection 60
Number of Products by Top 10 Targets, Graft Versus Host Disease (GVHD) 62
Number of Products by Stage and Top 10 Targets, Graft Versus Host Disease (GVHD) 62
Number of Products by Top 10 Mechanism of Actions, Graft Versus Host Disease (GVHD) 65
Number of Products by Stage and Top 10 Mechanism of Actions, Graft Versus Host Disease (GVHD) 65
Number of Products by Routes of Administration, Graft Versus Host Disease (GVHD) 68
Number of Products by Stage and Routes of Administration, Graft Versus Host Disease (GVHD) 68
Number of Products by Top 10 Molecule Types, Graft Versus Host Disease (GVHD) 70
Number of Products by Stage and Top 10 Molecule Types, Graft Versus Host Disease (GVHD) 70
Number of Products by Top 10 Targets, Liver Transplant Rejection 72
Number of Products by Stage and Top 10 Targets, Liver Transplant Rejection 72
Number of Products by Top 10 Mechanism of Actions, Liver Transplant Rejection 74
Number of Products by Stage and Top 10 Mechanism of Actions, Liver Transplant Rejection 74
Number of Products by Routes of Administration, Liver Transplant Rejection 76
Number of Products by Stage and Routes of Administration, Liver Transplant Rejection 76
Number of Products by Molecule Types, Liver Transplant Rejection 78
Number of Products by Stage and Molecule Types, Liver Transplant Rejection 78
Number of Products by Top 10 Targets, Kidney Transplant Rejection 80
Number of Products by Stage and Top 10 Targets, Kidney Transplant Rejection 80
Number of Products by Top 10 Mechanism of Actions, Kidney Transplant Rejection 82
Number of Products by Stage and Top 10 Mechanism of Actions, Kidney Transplant Rejection 82
Number of Products by Routes of Administration, Kidney Transplant Rejection 84
Number of Products by Stage and Routes of Administration, Kidney Transplant Rejection 84
Number of Products by Top 10 Molecule Types, Kidney Transplant Rejection 86
Number of Products by Stage and Top 10 Molecule Types, Kidney Transplant Rejection 86
Number of Products by Targets, Lung Transplant Rejection 88
Number of Products by Stage and Targets, Lung Transplant Rejection 88
Number of Products by Top 10 Mechanism of Actions, Lung Transplant Rejection 90
Number of Products by Stage and Top 10 Mechanism of Actions, Lung Transplant Rejection 90
Number of Products by Routes of Administration, Lung Transplant Rejection 92
Number of Products by Stage and Routes of Administration, Lung Transplant Rejection 92
Number of Products by Molecule Types, Lung Transplant Rejection 94
Number of Products by Stage and Molecule Types, Lung Transplant Rejection 94
Number of Products by Targets, Heart Transplant Rejection 96
Number of Products by Stage and Targets, Heart Transplant Rejection 96
Number of Products by Mechanism of Actions, Heart Transplant Rejection 98
Number of Products by Stage and Mechanism of Actions, Heart Transplant Rejection 98
Number of Products by Routes of Administration, Heart Transplant Rejection 100
Number of Products by Stage and Routes of Administration, Heart Transplant Rejection 100
Number of Products by Molecule Types, Heart Transplant Rejection 102
Number of Products by Stage and Routes of Administration, Heart Transplant Rejection 102 



To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global integrated systems market is projected to reach USD 24 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to re-evaluate data center infrastructure is expected to boost the demand. Change in trend from main

Read More...

Global alpha olefins market size is likely to be valued at USD 10.7 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing polyethylene demand for use in plastic production is anticipated to drive market growth. Growing ap

Read More...

Global automotive collision repair market is expected to be valued at USD 196.97 billion by 2020, as per a new research report by Radiant Insights, Inc. The industry is expected to witness significant growth owing to increasing number of on-road vehi

Read More...

Global compressed air treatment equipment market is projected to reach USD 8.59 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing implementation of this equipment in various industry sectors such as healthcare & pharmace

Read More...

Global automotive electronics market size forecast is likely to reach USD 279.96 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing application scope of these equipments is estimated to drive industry growth. Increasing i

Read More...
Choose License Type
Single User - US $3995
Multi User - US $7990
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify